Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jul 11, 2023

Keywords

ClinConnect Summary

This clinical trial is examining whether a special combination of two medications, dexmedetomidine and esketamine, can help improve sleep quality in older adults who are scheduled for knee or hip replacement surgery. Sleep problems can be common in these patients, and they can lead to complications like confusion or heart issues after surgery. The researchers believe that using low doses of these medications together at night may help patients sleep better during their recovery.

To participate in this trial, you must be between 65 and 89 years old and scheduled for a single knee or hip surgery. However, if you have certain medical conditions, such as severe sleep apnea, serious heart problems, or a history of certain neurological disorders, you may not be eligible. Participants will receive the treatment before their surgery and will be monitored for how well they sleep. This study aims to find a safer and more effective way to support sleep for older patients undergoing these surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥65 years and \<90 years;
• • Scheduled to undergo unilateral knee or hip arthroplasty.
• Exclusion Criteria:
• • Refuse to participate;
• • Hypnotic therapy for sleep disorders within 3 months;
• • Preoperative history of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;
• • Diagnosed as obstructive sleep apnea, or at high risk of moderate to severe obstructive sleep apnea according to the Stop-Bang questionnaire;
• • Inability to communicate in the preoperative period because of coma, profound dementia, or language barrier;
• • Sick sinus syndrome, severe sinus bradycardia (heart rate \<50 beats/min), or atrioventricular block above grade II without pacemaker implanted;
• • Severe hepatic dysfunction (Child-Pugh class C), renal dysfunction (required preoperative dialysis), or expected survival ≤24 hours;
• • Receiving treatment with dexmedetomidine, clonidine, or esketamine;
• • Allergy to dexmedetomidine or esketamine.